Avtor/Urednik		Bren, A; Kandus, A
Naslov		Epoetin omega requirements in the correction of anemia in hemodialysis patients
Tip		članek
Vir		Maked Med Pregl
Vol. in št.		Letnik 56, št. Suppl 59
Leto izdaje		2003
Obseg		str. 104-6
Jezik		slo
Abstrakt		The aim of the study was to evaluate the safety and effectiveness of epoetin omega (produced in BHK cells) in sustaining the correction of anemia in maintenace hemodialysis patients. The study was completed in 38 stable patients treated with epoetin omega for 24 weeks. Epoetin omega was administered subcutaneously after each dialysis. Doses were adjusted with the aim of maintaining a target hemoglobin level between 10 and 12 g/dL (hematocrit 30 to 35%). The mean weekly dose of epoetin omega/kg BW was 67 ± 43 U. The average of all mean values of hemoglobin during treatment with epoetin omega was 11.4 ± 0.7 g/dl (hematocrit 34 ± 2%). Thromboses of vascular access occurred in three patients during an epoetin omega treatment, and at the site of injection only one patient was presented with a mild pain. In conclusion, epoetin omega was effective in correcting the anemia of all studied patients. No serious side effects were noted. The authors think that further studies with epoetin omega with higher correction of anemia and a greater number of patients are needed to get better insight into activity and safety ofthis epoetin.
Deskriptorji		KIDNEY FAILURE, CHRONIC HEMODIALYSIS ANEMIA ERYTHROPOIETIN, RECOMBINANT HEMOGLOBINS BLOOD PRESSURE HEMATOCRIT IRON FERRITIN